Monday 7 October 2013, Amsterdam
Despite the success of antiretroviral therapy (ART) in the treatment of HIV, a significant unmet need remains for the cure and prevention of the disease, although a number of challenges stand in the way of novel non-ART interventions, says the latest report available on ASDReports.
The new report states that there is an ongoing need for interventions to control the HIV pandemic, including prophylactic vaccines, novel salvage therapies and an eventual cure for the condition, which will release patients from long-term ART.
Various efforts targeting different aspects of HIV are emerging, such as latency reversal agents and immunotherapies that educate the immune system to eliminate virus-infected cells. GlobalData now believes that the success of a functional cure could well come from an intervention which combines these approaches.
Dr. Charalampos Valmas, analyst covering infectious Disease, says: “The need for new combinatorial therapies presents a unique opportunity for small biotech companies and academic laboratories to combine their forces, and we expect that the first successful regimen will attract Big Pharma, which could use its resources to conduct large-scale trials and market the therapy successfully.”
However, a number of significant barriers have presented themselves to new HIV treatments, including the fact that vaccine research and development (R&D) has at present been deprioritised by Big Pharma.
Valmas continues: “Big Pharma does not consider HIV or other STD vaccines as lucrative as those for airborne diseases, such as influenza, due to the limited patient segments that an HIV vaccine would initially address. As a result, research is instead being conducted by biotech companies, as well as academic and government-funded institutes, which sadly may not possess the financial capabilities to proceed to Phase III trials.”
Publish date : August 2013
Report code : ASDR-76090
Pages : 111
ASDReports.com contact: S. Koomen
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216